Highlights • When reassessed, most cancer drugs did not exhibit substantial benefit. • Over a third of drug trials changed benefit classification at 3-year reassessment. • However, a nearly equal number of trials increased and decreased their benefit. • Thus, it may be useful to regularly reassess the benefit of approved cancer drugs. Abstract Background Increasingly, cancer drugs are being approved based on surrogate measurements of efficacy.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Noah
Contact Noah, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack